相关实验视频
Updated: Jul 15, 2025

09:25
ROS Live Cell Imaging During Neuronal Development
Published on: February 9, 2021
4.3K
新型NADPH氧化酶-2抑制剂作为潜在的抗炎和神经保护剂
Matea Juric1, Varun Rawat2, Radhika Amaradhi2
1Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Antioxidants (Basel, Switzerland)
|September 28, 2023
概括
研究人员开发了TG15-132,一种新型的大脑透性Nox2抑制剂. 在临床前研究中,这种化合物显示出作为神经保护剂的潜力,减少反应性氧物种和炎症,而不会引起毒性.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- NADPH氧化酶 (Nox) 酶,特别是Nox2,与各种疾病有关,包括神经退行性疾病.
- 开发大脑透性抑制剂对于向中枢神经系统疾病至关重要.
研究的目的:
- 为了识别和描述潜在的神经保护的新型脑透性Nox2抑制剂.
- 评估TG15-132作为Nox2抑制剂的疗效和安全性.
主要方法:
- 基于细胞的测试使用差异化的HL60和THP-1细胞来评估抑制剂活性.
- 测量氧气消耗和反应性氧物种 (ROS) 生产.
- 对Nox2亚单元,炎症性细胞因子和iNOS的基因表达分析.
- 在动物模型中进行的药理动力学研究 (血半衰期,脑透性).
- 在慢性剂量后对小鼠进行毒理评估.
主要成果:
- 在HL60细胞中,TG15-132有效地抑制了PMA刺激的氧气消耗和ROS形成.
- 长期的TG15-132治疗减少了THP-1细胞中Nox2亚单元,炎症性细胞因子和iNOS的基因诱导.
- TG15-132表现出有利的血半衰期 (5.6小时) 和显著的大脑透性 (>5倍的大脑与血的比率).
- 在长期用药7天后,在小鼠中没有观察到有毒效应.
结论:
- TG15-132是一种强效的,脑透的NOx2抑制剂,具有潜在的神经保护性质.
- 它降低氧化应激和炎症的能力,再加上良好的安全性,支持其进一步发展.
- 进一步的结构修改可能会提高TG15-132的治疗功效.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
332
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
332
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K

